$141.69
-2.68-1.86%
At close: Nov 13, 4:00 PM EST
$142.00
0.310.22%
After Hours: Nov 13, 6:12 PM EST
Axsome Therapeutics Inc
AXSMNASDAQ
Axsome Therapeutics (AXSM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $-0.25 | $-0.64 | 60.9 % |
| Q2 | Aug 10, 2026 | $-0.99 | $-0.87 | -13.8 % |
| Q1 | May 4, 2026 | $-1.26 | $-0.83 | -51.8 % |
| Q4 | Feb 23, 2026 | $-0.56 | $-0.72 | 22.2 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $259.69M | $248.64M | 4.45 % |
| Q2 | Aug 10, 2026 | $218.40M | $222.33M | -1.77 % |
| Q1 | May 4, 2026 | $191.20M | $190.28M | 0.48 % |
| Q4 | Feb 23, 2026 | $196.00M | $193.16M | 1.47 % |
Axsome Therapeutics (AXSM) last issued guidance on January 4, 2024 for fiscal year 2023. The company guided revenue in the range of $204M - $204M for the period.
Compared to prior guidance, Axsome Therapeutics raised its revenue forecast from a prior range of $71M - $71M.
Axsome Therapeutics has issued 2 guidance updates between January 4, 2024 and January 4, 2024. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.64 | $-0.87 | $-0.83 | $-0.72 |
| Actual | $-0.25 | $-0.99 | $-1.26 | $-0.56 |
| Surprise | +60.9% | -13.8% | -51.8% | +22.2% |
| Revenue | ||||
| Estimate | $248.6M | $222.3M | $190.3M | $193.2M |
| Actual | $259.7M | $218.4M | $191.2M | $196.0M |
| Surprise | +4.45% | -1.77% | +0.48% | +1.47% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.07 | $0.01 | $0.35 | $0.96 |
| Revenue | ||||
| Consensus | $283.1M | $296.6M | — | — |
